Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RDPTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radiopharm Theranostics Limited (RDPTF) SEC filings provide U.S. investors with access to information originally released to the Australian Securities Exchange. As a foreign private issuer, the company files annual reports on Form 20-F and furnishes current reports on Form 6-K under Rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
In its Form 6-K submissions, Radiopharm Theranostics Limited includes an explanatory note describing the public notice it published to the Australian Securities Exchange and attaches that notice as an exhibit. Examples include a filing that furnishes a "Corporate Governance Statement and Appendix 4G" and another that furnishes a "Pivalate (Brain Mets) key opinion leader webinar" announcement. These filings clarify that the reports, including exhibits, are not deemed "filed" for purposes of the Exchange Act and are not incorporated by reference into Securities Act filings unless specifically stated.
On this page, you can review Radiopharm Theranostics’ Form 6-K and Form 20-F submissions as they appear in the SEC’s EDGAR system. The platform offers real-time updates when new filings are furnished, along with AI-powered summaries that explain the key points in plain language. This can help readers understand the substance of governance documents like the corporate governance statement and Appendix 4G, as well as the focus of materials such as the Pivalate (Brain Mets) key opinion leader webinar.
In addition to current reports, investors can use this page to locate the company’s annual Form 20-F, which provides a broader overview of its status as a foreign private issuer. Where applicable, insider transaction reports on Form 4 and other relevant filings can also be accessed, with AI tools highlighting important sections and clarifying technical terminology.
Radiopharm Theranostics Limited (RDPTF) reported a challenging year ending June 30, 2025, with a total comprehensive loss of A$37.88 million and negative operating cash flows of approximately A$36.65 million. The group recorded accumulated losses of A$145.73 million and significant research and development investment, including R&D expenses of A$27.52 million (line item) and intangible assets on the balance sheet of A$49.09 million.
The company generated other income including an R&D tax incentive (A$9.37 million recognised) and raised cash from financing activities (A$45.43 million reported in one table). Key governance and management details are disclosed, including CEO Riccardo Canevari and a Board with named directors and option/share holdings. The filing also discloses material contingent consideration balances, significant finance expenses and assumptions used in impairment and contingent consideration models.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing furnishes as an exhibit a Public Notice dated September 17, 2025 titled “Corporate Governance Statement and Appendix 4G.”
The attached materials relate to the company’s corporate governance disclosures and associated compliance appendix. The Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated by reference into other Securities Act filings unless specifically referenced.
FAQ
What is the current stock price of Radiopharm Theranostics (RDPTF)?
